Kazia Therapeutics expands breast cancer trial enrollment to 36 patients

May 26, 2026 7:30 AM

Kazia Therapeutics Limited (NASDAQ: KZIA) announced plans to expand enrollment in its ongoing Phase 1b clinical trial of paxalisib in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found